Pfizer: Understanding Residual Cardiovascular Risk Related to Triglyceride-Rich Remnant Lipoproteins

Through this RFP, it is our intention to support educational programs focused on understanding residual cardiovascular (CV) risk associated with triglyceride (TG)-rich remnant lipoproteins by:

• Discussing the importance of understanding sources of CV risk beyond LDL-C
• Discussing relevant basic and clinical science related to TG-rich remnant lipoproteins versus serum TG in atherosclerosis and CV risk

Providing context for clinicians to use this information in clinical practice where appropriate

Funding: $100,000-$150,000; 24-month maximum.

https://www.pfizer.com/purpose/independent-grants/competitive-grants

https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-12/2021%20IM%20G%20-%20Understanding%20CVRR%20Related%20to%20Triglyceride-Rich%20Remnant%20Lipoproteins.pdf?p0xI6pbQD3ozjq53iLEUFRKxvyFui4w.